A 90-person trial found less weight regain with a specific pasteurised Akkermansia preparation over 24 weeks. Findings cannot be generalised to other supplements.
Browsing: Obesity & Weight Management
Evidence summaries for obesity and weight management, including lifestyle trials, pharmacotherapy, bariatric/metabolic outcomes, cardiometabolic risk, and long-term safety.
CARE-PWS did not meet its primary high-dose endpoints. Lower-dose hyperphagia findings were nominal secondary results, not a confirmatory efficacy success.
HISTORI tested semaglutide in schizophrenia with prediabetes and obesity. Review HbA1c and weight effects, gastrointestinal harms and psychiatric limitations.
ATTAIN-MAINTAIN tested oral orforglipron after tirzepatide or semaglutide. More prior weight loss was retained than with placebo; continued injections were not compared.
In a 16-week randomized study of women with obesity and PCOS, semaglutide improved taste recognition by an estimated 2.5 points versus placebo.
In a 16-person crossover trial, all light walking patterns lowered postprandial glucose and diastolic blood pressure versus sitting; only 30-minute continuous walks also lowered the insulin response.
In 83 older men with obesity and low testosterone, adding testosterone to 6 months of lifestyle therapy did not improve HbA1c further (-0.5% vs -0.6%; P=0.35) and blunted the HDL and adiponectin rise.
Adding topiramate to metformin improved 6-month weight loss in women with PCOS, but the benefit was modest and paresthesia was more common.
ATTAIN-1 found that oral orforglipron 36 mg reduced body weight by 11.2% versus 2.1% with placebo over 72 weeks in adults with obesity without diabetes.
In STEP UP, semaglutide 7.2 mg reduced body weight by 18.7% versus 3.9% with placebo and outperformed semaglutide 2.4 mg in adults with obesity without diabetes.